Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review

Rita Leporati(Fondazione IRCCS Istituto Nazionale dei Tumori), Laura Mezquita(Hospital Clínic de Barcelona), Édouard Auclin(Centre Hospitalier de l’Université de Montréal), Juan Carlos Laguna(Hospital Clínic de Barcelona), Paolo Ambrosini(Fondazione IRCCS Istituto Nazionale dei Tumori), Miquel Ferriol-Galmés(Universitat Politècnica de Catalunya), Teresa Gorría(Hospital Clínic de Barcelona), Dolores Isla(Hospital Clínico Universitario Lozano Blesa), Cristina Teixidó(Hospital Clínic de Barcelona), Giuseppe Lo Russo(Fondazione IRCCS Istituto Nazionale dei Tumori), M. Amores(Universidad de Salamanca)
Therapeutic Advances in Medical Oncology
January 1, 2024
10.1177/17588359241306940
Cited by 6

Related Papers

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
|The Lancet Oncology|2022|738
Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer
|Journal of Clinical Oncology|2005|454